Table 1.
Descriptive Characteristics of the Study Sample at Classified by BMI
| Low Weight (<18.5kg/m2) n=967 | Normal Weight (18.5–24.9 kg/m2) n=14,443 | Overweight (25.0–29.9 kg/m2) n=12,204 | Mild Obesity (30.0–34.9 kg/m2) n=2769 | Severe Obesity (≥35.0 kg/m2) n=310 | P value | |
|---|---|---|---|---|---|---|
| Female, n (%) | 488(50.5)a | 6493(45) | 5451(44.7) | 1374(49.6)a | 178(57.4)a | <0.001 |
| Age (year) | 71.5±12.5a | 68.4±12.4 | 66.8±12.9a | 65.0±14.7a | 61.9±17.1a | <0.001 |
| Diabetes duration (y) | 8.5±3.7a | 8.0±3.4 | 7.8±3.3a | 7.7±3.8a | 6.7±3.8a | <0.001 |
| Hypertension, n (%) | 506(52.3)a | 8784(60.8) | 8581(70.3)a | 2170(78.4)a | 246(79.4)a | <0.001 |
| CHD, n (%) | 268(27.7)a | 3235(22.4) | 2852(23.4) | 758(27.4)a | 89(28.7) | <0.001 |
| Smoking, n (%) | 162(16.9)a | 3017(21.2) | 2831(23.5)a | 716(26.2)a | 80(26.6) | <0.001 |
| Drinking, n (%) | 69(7.2) a | 1656(11.6) | 1656(13.7)a | 415(15.2)a | 44(14.6) | <0.001 |
| BMI (kg/m2) | 17.1±1.2a | 22.5±1.7 | 27.0±1.4a | 31.6±1.3a | 37.4±3.6a | <0.001 |
| Antiplatelet user, n (%) | 450(52.4) | 6309(49.0) | 5453(50.3) | 1235(50.6) | 135(48.7) | 0.112 |
| Statin user, n (%) | 338(39.4) | 5192(40.3) | 4407(40.7) | 978(40.1) | 111(39.8) | 0.944 |
| Insulin user, n (%) | 518(60.4) | 7984(61.9) | 6647(61.2) | 1434(58.5)a | 164(58.8) | 0.028 |
| Metformin user, n (%) | 162(18.9)a | 2972(23.0) | 2711(25.0)a | 593(24.2) | 70(25.1) | <0.001 |
| FBG (mmol/L) | 10.4±5.8 | 10.2±5.3 | 10.1±4.9 | 10.2±4.7 | 10.2±5.4 | 0.125 |
| HbA1c (%) | 8.3±2.4 | 8.2±2.2 | 8.1±2.0a | 8.1±2.0 | 8.1±2.0 | 0.010 |
| Hypoglycemia, n (%) | 17(1.8) | 179(1.3) | 128(1.1) | 19(0.7)a | 3(1.0) | 0.032 |
| T-CHO (mmol/L) | 4.3±1.2a | 4.5±1.4 | 4.5±1.3a | 4.6±1.3a | 4.6±1.2 | <0.001 |
| HDL-C (mmol/L) | 1.2±0.3a | 1.1±0.3 | 1.1±0.3a | 1.1±0.3a | 1.1±0.3 | <0.001 |
| LDL-C (mmol/L) | 2.6±0.9a | 2.7±0.9 | 2.8±1.0a | 2.8±0.9a | 2.8±1.0 | <0.001 |
| Triglyceride (mmol/L) | 1.2 (0.8–1.7)a | 1.4 (1.0–2.1) | 1.6 (1.1–2.3)a | 1.7 (1.2–2.5)a | 1.8 (1.3–2.5)a | <0.001 |
| Apolipoprotein-A1 (g/L) | 1.1±0.3 | 1.1±0.3 | 1.1±0.3a | 1.1±0.3a | 1.1±0.3 | 0.023 |
| Apolipoprotein-B (g/L) | 0.8±0.2a | 0.8±0.2 | 0.8±0.3a | 0.8±0.2a | 0.8±0.3 | <0.001 |
| Lipoprotein-a (mg/L) | 232 (117.5–400.5)a | 197 (103–349) | 186 (97–330.5)a | 182 (99–326)a | 160 (73.8–318.3)a | <0.001 |
| BUN (mmol/L) | 7.3±5.1a | 6.8±4.6 | 6.7±4.5 | 6.7±4.6 | 6.8±4.6 | 0.003 |
| SCr (umol/L) | 73 (60–95) | 74 (61–92) | 76 (63–94)a | 75 (62–94)a | 74 (60–92.5) | <0.001 |
| SUA (umol/L) | 272.2±131.7a | 289.3±121.3 | 305.3±123.2a | 313.1±133.2a | 334.4±143.8a | <0.001 |
Notes: Data are mean±SD, median (interquartile range), or n (%). ap < 0.05 compared to Normal weight group.
Abbreviations: BMI, body mass index; CHD, coronary heart disease; FBG, fasting blood-glucose; HbA1c, glycosylated hemoglobin; T-CHO, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BUN, blood urea nitrogen; SCr, serum creatinine; SUA, serum uric acid.